Ex Vivo Drug Testing
Ex Vivo Drug Testing - Related Videos
09:16
Simultaneous ex vivo Functional Testing of Two Retinas by in vivo Electroretinogram System
0 Views •
Cited by 36 •
2015
Ex vivo ERG can be used to record electrical activity of retinal cells directly from isolated intact retinas of animals or humans. We demonstrate here how common in vivo ERG systems can be adapted for ex vivo ERG recordings in order to dissect the electrical activity of retinal cells.
09:24
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
0 Views •
Cited by 20 •
2016
Patient-derived xenografts of glioblastoma multiforme can be miniaturized into living microtumors using 3D human biogel culture system. This in vivo-like 3D tumor assay is suitable for drug response testing and molecular profiling, including kinomic analysis.
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
0 Views •
Cited by 4 •
2015
Here, real-time monitoring of tumor cell metabolism, combined with an in vivo chicken embryo chorio-allantoic membrane (CAM) model of metastasis, are used to evaluate novel anti-cancer targets/agents for their ability to sensitize tumor cells to DNA damaging chemotherapeutics.
09:58
Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
0 Views •
Cited by 37 •
2015
A protocol for robotic printing of cancer cell spheroids in a high throughput 96-well plate format using an aqueous two-phase system is presented.
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
0 Views •
Cited by 6 •
2016
This manuscript describes the development of an animal model that allows for the direct testing of the effects of tumor hypoxia on metastasis and the deciphering the mechanisms of its action. Although the experiments described here focus on Ewing sarcoma, a similar approach can be applied to other tumor types.
FAQs
Removing a sample from the organism preserves cellular interactions and aspects of tissue or organ function that may be absent from simpler laboratory models. This can reveal responses that depend on the organization of living material, while laboratory control allows researchers to expose samples to defined drug concentrations. The resulting balance supports more biologically informative testing than measurements from isolated components alone.
Ex vivo testing occupies an intermediate position between simplified in vitro systems and whole-animal studies. It uses living cells, tissues, or organs outside the organism, retaining some native biological features while permitting controlled drug exposure and direct response assessment. Because it complements rather than replaces in vitro and animal approaches, researchers can use it to refine experimental design and support translational research.
Defined drug concentrations make responses easier to compare across samples and help link exposure to observed molecular, functional, efficacy, or toxicity outcomes. Sample condition also matters because material may be freshly isolated or preserved before testing. Maintaining the selected material under laboratory conditions provides the basis for interpreting whether an observed response reflects the compound, the biological sample, or both.
Assessment can include molecular changes, tissue function, therapeutic efficacy, and toxicity. These endpoints address different questions: molecular measurements indicate biological change, functional measurements show whether tissue behavior is altered, and efficacy or toxicity assessments address benefit and harm. Considering several response types can provide a broader picture of how a compound affects patient-derived or other biological material.
A typical workflow begins with obtaining living cells, tissue, or an organ and maintaining the material under laboratory conditions. The sample is then exposed to selected drug concentrations, followed by assessment of molecular changes, tissue function, efficacy, or toxicity. The specific endpoint depends on the research question, but consistent handling and controlled exposure are central to comparing responses.
Patient-derived material can help investigators examine how an individual's biological sample responds to a therapeutic compound before clinical administration. This supports disease modeling and may contribute to personalized treatment decisions. The approach is especially informative when researchers need response data connected to patient material, while recognizing that the testing complements broader experimental and clinical evaluation rather than replacing it.
The method links controlled laboratory experiments with questions about therapeutic response in biologically relevant material. By showing molecular, functional, efficacy, or toxicity changes, it can help guide compound evaluation and refine later experimental designs. Its role alongside in vitro systems and animal studies provides complementary evidence that may support progression from disease models toward medically relevant investigation.